Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: carlumab | 0.81 |
| trials ClinicalTrials.gov | 5 Parkinson's trials, 1 stopped | 0.84 |
| literature PubMed | PubMed did not answer (PubMed: HTTP 500) | 0.00 |
| pathways Reactome | 6 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 3410
Sealed predictions
- CCL2 in dopamine neurons, braak+0.28 (p 0.472) → -0.18 (p 0.648)receipt 3417
Swarm cases
receipt 3417: CCL2 in dopamine neurons, braak
- power
- full sample -0.04 (p 0.888, n 18), 95% CI -0.49 to +0.44. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.04 (p 0.881, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.02 (p 0.942, n 18). could be the mix.
- skeptic
- leave-one-out range -0.17 to +0.07, sign flips 5; without severely affected donors -0.04 (p 0.888, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CCL2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts